- Studies from the National Institutes of Health have shown that J&J produces a stronger immune response than two doses of J&J as a booster among MRNA vaccines after a shot.
- In response to the study, Johnson & Johnson noted that a booster of its vaccine increased a person’s immunity regardless of their previous initial vaccination.
- The FDA’s Vaccine and Related Organic Products Advisory Committee met Thursday to discuss the Modern Booster and Friday’s J&J Booster.
The best booster for the Johnson & Johnson Covid-1 vaccine could be Pfizer-Biotech or Modern, according to the National Institutes of Health posted Wednesday.
“People were waiting for a big study of Mix and Match, it gave a lot of new information and there was nothing before about the mRNA booster about Johnson & Johnson,” said Dr. Eric Topol, vice president of research. National expert on data use in Scripps research and medical research in La Jolla, California.
The study, which included about 500 people, found that mRNA vaccines produced a stronger immune response than two doses of J&J as a booster after a shot of J&J.
Booster doses of the mRNA vaccine were effective for those who received the Pfizer or Modernna two-dose series.
The new study comes just days before a new Food and Administration Advisory Committee began discussions on a possible booster dose of Moderena and the J&K vaccine. The Pfizer booster was approved on September 24th.
Keep in touch: Subscribe to Coronavirus Watch, your daily updates on all aspects of Covid-1 all in USA
Data from the NIH study will be presented to the FDA committee on Friday afternoon, according to the meeting agenda, for those who have already received similar shots are likely to vote on potential J&J booster shots.
This study by the Mix and Match team was sponsored by the National Institutes of Health. It compared all possible combinations of the three vaccines followed by a booster.
“If you look at the mix and match data, you’ll say, ‘Wow, I really want to get an mRNA booster.’ It basically transforms Johnson & Johnson into a good MRNA two-shot series, ” Topol said.
The study volunteers were divided into three groups. One received a two-dose series of Pfizer vaccines, a modern two-dose series and a “one and done” J&J vaccine.
Each group was then divided into three smaller groups. Got a Pfizer as their booster, a Moderna and a J&J.
Participants’ antibody levels against Covid-1 were measured two weeks later and four weeks after receiving their booster shot.
Everyone who gets Pfizer or Moderna series and Pfizer or Moderna as a booster gets the same protection.
The lowest antibody levels were for people who received a J&J shot and then a J&J booster.
‘Naked in the cove world’:Some J&J vaccine recipients feel insecure against the delta and want mRNA shots
In response to the study, Johnson & Johnson noted that a booster of its vaccine increased a person’s immunity regardless of their previous initial vaccination.
“Johnson & Johnson will continue to share available boosting data with the US Food and Drug Administration (FDA) and other regulators and look forward to discussing the latest available data in this week’s Vaccine and Related Organic Products Advisory Committee.
The NIH study did not include real-world data on how effective vaccines and boosters were in preventing mild or severe Covid-1. However, the antibody response is considered to be a good indicator of the effectiveness of the vaccine.
There is some similar real world data outside of Spain and the UK. Those who received the AstraZeneca vaccine, which was a similar or J&J vaccine and then had higher levels of antibodies to a Pfizer booster.
The FDA committee meets Thursday and Friday at the Modena, J&J boosters
The FDA’s Vaccine and Related Organic Products Advisory Committee met Thursday to discuss the Modern Booster and Friday’s J&J Booster.
In a briefing document posted Wednesday, a small study of 17 individuals who received J&J booster shots six months after presenting their first shot.
There are many large studies in J & J’s work but no data has been provided to the FDA, which decides whether to allow a booster. It is not clear whether the small group of recipients is enough for the agency to approve the six-month booster.
Tracking distribution of Covid-1 vaccine by state:How many people have been vaccinated in the United States?
“It was hoped that we would resolve this issue and that J&J would approve their emergency use for their booster. Things are a little complicated now, ”said Dr. William Schaffner, medical director of the National Foundation for Infectious Diseases.
Safety information for J&J booster recipients was good, and according to the FDA, the vaccine “still provides protection against serious COVID-19 diseases and deaths,” although less so than Pfizer-BioNTech and Moderna mRNA-based vaccines.
In his briefing document, J&J said a booster could be given within two to six months of the initial shot, depending on who got the shot and how strong their resistance was.
About 15 million Americans have been fully vaccinated with the J&J vaccine, compared to 103 million who received Pfizer and 69 million who received Modern. So far, 8.8 million Americans have received a booster dose of the Pfizer vaccine.